Invion Ltd. · ASX:IVX
Invion — Investor Presentation (December 2017)
37 slides from Invion's investor presentation, December 2017
Slide 1: INVION
INVION
Slide 2: Invion Investor Update
INVION INVESTOR UPDATE Strategic Transaction with The Cho Group to develop and commercialise the New Generation PhotoDynamic Therapy, Photosoft™, targeted to the treatment of solid cancers
Slide 3: Invion Strategy in 2017
INVION STRATEGY IN 2017 AIM: OUTCOME: Identify and pursue opportunities to Licence to develop and commercialise reshape and enhance the company’s Photosoft™ for the treatment of cancers pipeline and business growth Agreement that provides non-dilutive funding for asset development
Slide 4: Strategic Transaction with The Cho Group
R&D Services Agreement: Invion will conduct clinical development of Photosoft™ globally, STRATEGIC leveraging the Company’s expertise. The Cho Group will provide non- dilutive funding for R&D and clinical TRANSACTION trials as part of a global development strategy for the asset 1 3 WITH THE CHO GROU
Slide 5: What is Photo Dynamic Therapy (PDT)?
WHAT IS PHOTO DYNAMIC THERAPY (PDT)? Use of light to destroy cancerous cells or other abnormal tissue When exposed to specific wavelengths of light, photosensitizing agents produce a form of oxygen that causes destruction of nearby cells without damaging nearby tissue Wavelength determines how far t
Slide 6: How PDT Works
Photosensitizing 1 HOW PDT agent is taken (by mouth) or given (intravenously) The agent circulates through 2 WORKS the body and concentrates at the site of the tumour Light of specific wavelengths is 3 shone on the body which activates the reaction in the tumour The tumour is 4 selectively destroyed
Slide 7: PDT in Practice
PDT IN PRACTICE PDT IS USUALLY PERFORMED AS AN OUTPATIENT PROCEDURE There are a number of clinics throughout Australia that offer PDT therapy for the treatment of superficial skin cancers, and sunspots, including solar keratoses PDT may be repeated and may be used with other therapies, such as surge
Slide 8: History of Photodynamic Therapy
HISTORY OF PHOTODYNAMIC THERAPY 1903 1904 1925 1942 1958 Nobel Prize Von Tappeiner: Nobel Prize Porphrins: Light Bed therapy N. Finsen: PD reaction first H. Fischer: First used in for Neonatal Light therapy shown Porphyrins treatments Jaundice for skin description conditions
Slide 9: Dougherty: Photofrin therapy
1971-85 1990 2006 Dougherty: Russian and Windahl et al. Moore & Photofrin Chinese PDT (Denmark): PDT Emberton therapy developments for local (England): NASA & RSA prostate Interstitial cancer prostate PDT
Slide 10: First Generation Photosensitizers
PDT therapy became ‘mainstream’ in Variants of 1995 with the FDA PhotofrinⓇ Tended to remain approval of Photofrin were in the body for Ⓡ (porfimer sodium) subsequently long periods for treatment developed in of esophageal clinical trials cancer HOWEVER FIRST Does not absorb GENERATION PDT Fat solub
Slide 11: Second Generation Photosensitizers
PDT therapy became Strong absorption ‘mainstream’ in Variants of and longer 1995 Largely with the FDA Water soluble Photofrin Ⓡ Tended to remain with good wavelengths approval of Photofrin chlorophyll were in the body allowing for deeper Ⓡ (porfimer sodium) tissue subsequently long periods based dis
Slide 12: New Wave of Interest with Tookad
NEW WAVE OF INTEREST WITH TOOKAD STEBA BIOTECH CONDUCTED PH III IN 208 “Localised, low-risk prostate cancer can be PATIENTS WITH LOW-RISK PROSTATE CANCER: treated in a way that not only preserves genitourinary function but also results in a TOOKAD ACTIVE lower progression rate, a greater chance of G
Slide 13: New Generation Photo Dynamic Therapy: Photosoft
NEW GENERATION PHOTO DYNAMIC THERAPY: PHOTOSOFT™ Invion to in-licence asset based on patented PDT agent Photosoft™ Targeted to address limitations of 1st Generation PDT therapies Uses a laser light activation method based on a short, pulsating Near Infrared (NIR) wavelengths High photodynamic effici
Slide 14: Photosoft
PHOTOSOFT™ Chlorophyll-based PDT photosensitiser Complex of chlorin and chlorophyllin ACTIVATES AT MULTIPLE SENSITIVITY RANGES ACROSS A BROAD SPECTRUM
Slide 15: Photosoft Advantages
CURRENTLY AVAILABLE PHOTOSOFT™ THERAPIES PHOTOSOFT™ ADVANTAGES 1 Activation at multiple ranges allows deeper tissue penetration for the light source Water soluble Good bioavailability – can be administered 2 sublingually and intravenously Chlorin-e6 and Chlorophyllin-A are used Positive immune respo
Slide 16: 1st Generation vs Photosoft
1ST GENERATION VS PHOTOSOFT™ LIMITATION 1ST GENERATION PDT PHOTOSOFT™ Fast body clearance time from normal cells and tissue structures as well CLEARANCE 2 to 3 months clearance time. This causes extreme light sensitivity as organs. Combined with high cancer cell selectivity allows patients to TIME a
Slide 17: Localised Prostate Cancer: The State of Play
LOCALISED PROSTATE CANCER: THE STATE OF PLAY INCREASING NUMBERS OF MEN ARE CHOOSING ACTIVE SURVEILLANCE OVER SURGERY OR RADIOTHERAPY BECAUSE OF THE RISKS OF THESE TREATMENTS Active surveillance was ~6% of US patients 15 years ago, now 40% Surgery and radiotherapy are radical treatments associated wi
Slide 18: Early Studies of Photosoft Conducted in Australia
EARLY STUDIES OF PHOTOSOFT™ CONDUCTED IN AUSTRALIA PHASE I | PROSTATE CANCER 2013 2017 o Photosoft™ was administered to 68 prostate cancer patients by o A second Phase I was completed by Donald Murphy in Urologist Donald Murphy and collaborators collaboration with Monash University o Results for 26
Slide 19: A New Wave: Immunotherapy and PDT
A NEW WAVE: IMMUNOTHERAPY AND PDT Immune response is important in the control of tumour 2013 2017 growth o Photosoft was administered to 68 prostate cancer patients by o A second Phase I was completed by Donald Murphy in Urologist Donald Murphy and collaborators collaboration with Monash University
Slide 20: Phase I Prostate Cancer Data
PHASE I PROSTATE CANCER DATA 86 proteins relating to immune responses were observed Proteins relating to certain immune response pathways are enriched and were significantly over-represented within the dataset
Slide 21: Advantages of NGPDT and Photosoft
ADVANTAGES OF NGPDT AND PHOTOSOFT™ The immune response observed by Murphy in the Phase I provides potential advantages over other water-soluble PDT therapies such as TookadⓇ There is a growing body of knowledge that PDT has the potential to generate an anti-cancer immune response TookadⓇ Ph III succ
Slide 22: PDT Therapies Target Early-Stage Treatment
TARGETS Skin cancers including melanoma, squamous cell carcinoma & basal PDT THERAPIES cell carcinoma TARGET EARLY-STAGE Lung cancer TREATMENT AS NON-INVASIVE Prostate or Ovarian cancer AND REPEATABLE
Slide 23: First Steps: Funded with Non-Dilutive Capital
FIRST STEPS: FUNDED WITH NON-DILUTIVE Establish Scientific Explore short term Develop ovarian CAPITAL Advisory Board, opportunities for cancer strategy as and timing/ costs of treatment of skin the next clinical Phase II/ III clinical cancers and other opportunity for trials in prostate disorders Ph
Slide 24: Acquisition/Licensing Opportunities
ACQUISITION/ LICENSING OPPORTUNITIES INV103 (Cpn10) INV102 (Nadolol) INV104 (Zafirlukast) Current assets have completed programmed clinical development Management remains committed to licensing the assets
Slide 25: Management Team
MANAGEMENT TEAM POST-CURRENT TRANSACTION Mr Thian Chew Dr Greg Collier Dr Mitchell Glass Melanie Farris Other (Invion, Inc). Board changes Non-Executive Interim Chief Executive Executive Head of anticipated to Chairman Officer Chair Chief Medical Operations and occur in 2018 Officer Company Secretar
Slide 26: Company Snapshot and Impact of Transaction
COMPANY SNAPSHOT AND IMPACT OF TRANSACTION The effect of the proposed transaction on the Overall ownership structure of the Company after capital structure of the Company completion of the Underwritten Rights Issue Number of Percentage of Shares issued capital Shares on issue at the date of the Noti
Slide 27: Important Dates: Indicative Timetable
IMPORTANT Notice of Meeting lodged with ASX DATES: Monday, 30 October 2017 and dispatched to Shareholders INDICATIVE Monday, 13 November Invion Investor Session TIMETABLE Thursday, 30 November 2017 Date of Annual General Meeting Issue of Shares under the Thursday, 7 December 2017 Exclusive Distribut
Slide 28: INVION
INVION
Slide 29: Resource Slides
RESOURCE SLIDES INVION
Slide 30: What is Photodynamic Therapy?
WHAT IS PHOTODYNAMIC THERAPY? Photodynamic therapy (PDT) was developed at Roswell Park Cancer Institute (RPCI) in the late 1970s by Thomas Dougherty, PhD PDT is a treatment that uses a light sensitive drug – a photosensitiser - and non-thermal visible red light, typically generated by a laser When p
Slide 31: PDT Mechanism of Action
PDT MECHANISM OF ACTION PHOTODYNAMIC THERAPY (PDT) uses non-toxic photosensitisers and harmless visible light in combination with oxygen to produce cytotoxic reactive oxygen species that kill malignant cells by apoptosis and/or necrosis, shut down the tumour microvasculature and stimulate the host i
Slide 32: Research Output: MD Anderson Centre
RESEARCH OUTPUT: MD ANDERSON CENTRE Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly redu
Slide 33: PDT in Practice
PDT IN PRACTICE The light used for PDT can come from a laser or other sources o Laser light can be directed through fiber optic cables to deliver light to areas inside the body. For example, a fiber optic cable can be inserted through an endoscope into the lungs or esophagus to treat cancer in these
Slide 34: Comparable Company: Photocure
COMPARABLE COMPANY: PHOTOCURE US$77m Norweigian specialty Provides “important qualities pharmaceutical company that enhance the properties focusing on urology of photodynamic technology for diagnosis and therapy. cap on Oslo Bors and its Photocure Technology® platform Uniquely selective for diseased
Slide 35: Second Generation Photosensitizers
Strong absorption Water soluble and longer Largely with good chlorophyll wavelengths tissue allowing deeper based distribution penetration of tissues Low circulation BETTER times so patients Different TUMOR are not left chemistry SPECIFICITY vulnerable to SECOND sunlight damage GENERATION PHOTOSENSI
Slide 36: Management Team
MANAGEMENT TEAM CURRENT Dr Greg Collier Dr Mitchell Glass Melanie Farris (Invion, Inc). Interim Executive Head of Chair Chief Medical Operations and Officer Company Secretary
Slide 37: Management Team
MANAGEMENT TEAM POST-CURRENT TRANSACTION Mr Thian Chew Dr Greg Collier Dr Mitchell Glass Melanie Farris Other Chief Executive (Invion, Inc). Board changes Non-Executive Head of Officer anticipated to Chairman Chief Medical Operations and occur in 2018 Officer Company Secretary